Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Quest Diagnostics (NYSE:DGX) from Market ...

Quest Diagnostics (DGX) announced that Adrienne Brott has been named senior vice president and chief quality and regulatory affairs officer.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $175.3, a high estimate of ...

Leerink upgraded Quest Diagnostics (DGX) to Outperform from Market Perform with a price target of $174, up from $169. The firm notes its view ...

Shares of Quest Diagnostics Inc. DGX inched 0.64% higher to $151.92 Friday, on what proved to be an all-around favorable ...

Several research analysts recently issued reports on the stock. Barclays upped their price target on shares of Quest Diagnostics from $154.00 to $168.00 and gave the stock an “equal weight ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BofA raised the firm’s price target on Quest Diagnostics (DGX) to $182 from $179 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Adrienne L. Brott, an accomplished quality and regulatory affairs healthcare leader ...

Quest Diagnostics Inc.’s DGX continued momentum in the base business is poised to help it grow in the upcoming quarters. The ongoing adoption of the highly specialized Advanced Diagnostics services is ...

DGX has been the subject of several other research reports. Citigroup raised their target price on shares of Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a ...